Moderna’s COVID-19 vaccine candidate can remain stable for longer in a standard refrigerator

/ / News

Shares of Moderna Inc. shot up 11% in premarket trading Monday, after the biotechnology company said its COVID-19 vaccine candidate mRNA-1273 now remains stable at refrigerated temperatures for longer times. The company said mRNA-1273 can now remain stable at 2 degrees to 8 degrees Celsius (36 degrees to 46 degrees Fahrenheit), which is the temperature of a standard home refrigerator, for 30 days, an extension from an earlier estimate of seven days. At negative 20 degrees Celsius (negative 4 degrees Fahrenheit), it mRNA-1273 can remain stable for up to 6 months. It can remain stable at room temperature for up to 12 hours. The company said the vaccine won’t require dilution or special handling, which means vaccination can be made in a range of settings, including pharmacies and physicians’ offices. “We are pleased to submit these extended stability conditions for mRNA-1273 to regulators for approval,” said Chief Technical Operations and Quality Officer Juan Andres. “The ability to store our vaccine for up to 6 months at -20deg C including up to 30 days at normal refrigerator conditions after thawing is an important development and would enable simpler distribution and more flexibility to facilitate wider-scale vaccination in the United States and other parts of the world.” Moderna’s stock has rocketed 357% year to date through Friday, while the S&P 500 has gained 11%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.